PAR 20.4% 32.5¢ paradigm biopharmaceuticals limited..

From the announcement; "Early indications suggest that the...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 5,518 Posts.
    lightbulb Created with Sketch. 12
    From the announcement;
    "Early indications suggest that the formulation used in the allergic rhinitis clinical trial may need to be optimised"

    These indications are from the field presumably not Paul Rennie or PAR staff. It looks like the solution will be in the formulation.
    I do not know how these tests are designed but may be a better way would be to increase formulation in small numbers till it works. Within safety margins , which if I remember correctly were at least an order of magnitude away from potential harm.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
32.5¢
Change
0.055(20.4%)
Mkt cap ! $82.30M
Open High Low Value Volume
27.5¢ 33.5¢ 27.5¢ $1.328M 4.323M

Buyers (Bids)

No. Vol. Price($)
1 4624 32.5¢
 

Sellers (Offers)

Price($) Vol. No.
33.0¢ 152597 4
View Market Depth
Last trade - 16.10pm 22/11/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.